S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

Kura Oncology (KURA) Stock Forecast, Price & News

+0.46 (+3.79%)
(As of 05/20/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
631,682 shs
Average Volume
666,098 shs
Market Capitalization
$839.00 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

Kura Oncology logo

About Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications. The company has a clinical collaboration with Novartis to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression or PIK3CA mutation and/or amplification. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$7.15 per share


Net Income
$-130.47 million
Pretax Margin




Free Float
Market Cap
$839.00 million

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.09 out of 5 stars

Medical Sector

480th out of 1,416 stocks

Pharmaceutical Preparations Industry

209th out of 677 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology
or view top-rated stocks.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Kura Oncology

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) announced its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.52) by $0.03. During the same quarter in the prior year, the business posted ($0.46) EPS.
View Kura Oncology's earnings history

What price target have analysts set for KURA?

6 brokerages have issued 1 year target prices for Kura Oncology's shares. Their forecasts range from $26.00 to $80.00. On average, they anticipate Kura Oncology's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 201.8% from the stock's current price.
View analysts' price targets for Kura Oncology
or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?
Kura Oncology's management team includes the following people:
  • Dr. Troy Edward Wilson J.D., Ph.D., Chairman, CEO, Pres & Principal Financial Officer (Age 53, Pay $1.11M)
  • Ms. Kathleen Ford, Chief Operating Officer (Age 75, Pay $683.4k)
  • Dr. Marc Grasso M.D., Advisor (Age 48, Pay $715.95k)
  • Ms. Kirsten Flowers, Chief Commercial Officer (Age 46, Pay $661.25k)
  • Dr. Stephen Dale M.D., Chief Medical Officer (Age 50, Pay $398.93k)
  • Mr. Thomas Doyle, Principal Accounting Officer & Sr. VP of Fin. and Accounting (Age 51)
  • Mr. Pete De Spain, Sr. VP of Investor Relations & Corp. Communications
  • Mr. James E. Basta J.D., Esq., Chief Compliance Officer & Corp. Sec. (Age 56)
  • Ms. Teresa Brophy Bair Esq., J.D., Chief Legal Officer & Corp. Sec. (Age 51)
  • Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing
What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.42%), Deerfield Management Company L.P. Series C (6.63%), Suvretta Capital Management LLC (5.84%), Deep Track Capital LP (5.12%), Vanguard Group Inc. (5.00%) and State Street Corp (4.95%). Company insiders that own Kura Oncology stock include Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology

Which institutional investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Invesco Ltd., Wellington Management Group LLP, Candriam Luxembourg S.C.A., BlackRock Inc., Citigroup Inc., State Street Corp, SG Americas Securities LLC, and AlphaCrest Capital Management LLC.
View insider buying and selling activity for Kura Oncology
or view top insider-selling stocks.

Which institutional investors are buying Kura Oncology stock?

KURA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Deerfield Management Company L.P. Series C, Deep Track Capital LP, Aaron Wealth Advisors LLC, Eventide Asset Management LLC, Verition Fund Management LLC, Affinity Asset Advisors LLC, and Suvretta Capital Management LLC.
View insider buying and selling activity for Kura Oncology
or or view top insider-buying stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $12.59.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $839.00 million. The company earns $-130.47 million in net income (profit) each year or ($1.990010) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 121 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 500-8800 or via email at [email protected].

This page was last updated on 5/22/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.